NCT01014793已完成不适用
Short and Long Term Efficacy of Combined Treatment in Controlling IGI-I Levels in Acromegaly
Federal University of São Paulo1 个研究点 分布在 1 个国家目标入组 19 人开始时间: 2005年5月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Control of IGF-I levels
研究概览
简要总结
In acromegaly, nearly 40% of patients fail to control GH/IGF-I levels with somatostatin analogues (SA). Dopaminergic agonists (DA) are even less effective, but combination therapy with SA and DA normalizes IGF-I levels in 33-56% of patients in short-term studies. This study was designed to evaluate short and long term efficacy of cabergoline in controlling IGF-I levels in acromegalic patients receiving octreotide.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Active disease, under octreotide treatment at least 9 months
排除标准
- •Cabergoline allergy
研究组 & 干预措施
Responders to cabergoline
patients with active disease under octreotide treatment received addition of increasing doses of cabergoline (1.0, 2.0 and 3.5mg/week)
干预措施: cabergoline (Drug)
结局指标
主要结局
Control of IGF-I levels
时间窗: six months
次要结局
- control IGI-I levels(six months)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Effects of Therapies in the Acromegaly Disease: Acral Morpho-functional StudyAcromegalyNCT05964712Istituto Auxologico Italiano30
已完成
不适用
Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?AcromegalyNCT02152124University Hospital, Ghent21
已完成
不适用
Acromegaly Treatment Quality of Life StudyAcromegalyNCT01732406Massachusetts General Hospital126
已完成
3 期
Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland MacroadenomaAcromegalyNCT00690898Ipsen108
已完成
不适用
Co-treatment With Pegvisomant and a Somatostatin Analogue (SA) in SA-responsive Acromegalic PatientsImpaired Glucose ToleranceInsulin ResistanceAcromegalyNCT00652379University of Aarhus18